一项2025年的研究发现更年期激素疗法不会增加BRCA前乳癌变异妇女乳腺癌的风险, A 2025 study finds menopausal hormone therapy doesn’t raise breast cancer risk in BRCA-mutation women with prior breast cancer, challenging current guidelines.

2025年在圣安东尼奥乳腺癌专题讨论会上提交的一项研究发现,患BRCA1或BRCA2突变、有乳腺癌史的妇女的更年期激素治疗不会增加乳腺癌风险。 A 2025 study presented at the San Antonio Breast Cancer Symposium found that menopausal hormone therapy (HRT) does not increase breast cancer risk in women with BRCA1 or BRCA2 mutations who have a history of breast cancer. 研究人员分析了676对匹配的BRCA携带者,主要是卵巢切除术后,发现HRT使用者中乳腺癌累积发病率较低 (24.5%与42.9%相比),死亡率降低,特别是仅用雌激素治疗. Researchers analyzed 676 matched pairs of BRCA carriers, mostly post-oophorectomy, and found a lower cumulative breast cancer incidence among HRT users (24.5% vs. 42.9%) and reduced mortality, especially with estrogen-only therapy. 没有发现雌激素-孕激素治疗显著增加风险,这与目前的指导方针相反,这些指导方针通常不鼓励在高风险组中接受HRT. No significant risk increase was seen with estrogen-progestin therapy, challenging current guidelines that often discourage HRT in this high-risk group.